TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Actinogen Medical ( (AU:ACW) ) is now available.
Actinogen Medical held its 2025 Annual General Meeting in Sydney, where the Chair and CEO presented updates on their clinical trials and strategic direction. The company is advancing its XanaMIA Phase 2b/3 trial for Alzheimer’s disease, with full enrollment expected by the end of 2025 and initial results in early 2026. The XanaCIDD trial for depression showed significant benefits, reinforcing the potential of Xanamem in treating cognitive and depressive symptoms. These developments position Actinogen as a promising player in the biotechnology industry, with potential implications for stakeholders in terms of future treatment options and market growth.
More about Actinogen Medical
Actinogen Medical is an ASX-listed biotechnology company focused on developing novel therapies for neurological and neuropsychiatric diseases linked to dysregulated brain cortisol. Their lead compound, Xanamem, is being developed as a treatment for Alzheimer’s Disease, Depression, and potentially Fragile X Syndrome, addressing a significant unmet need for effective treatments in these areas.
Average Trading Volume: 3,723,869
Technical Sentiment Signal: Buy
Current Market Cap: A$165.3M
Learn more about ACW stock on TipRanks’ Stock Analysis page.